Dicerna Pharmaceuticals Inc

-0.08 (-0.20%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)2.97B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$41.26 Million
Adjusted EPS-$0.47
See more estimates
10-Day MA$36.62
50-Day MA$25.10
200-Day MA$27.96
See more pivots

Dicerna Pharmaceuticals Inc Stock, NASDAQ:DRNA

75 Hayden Avenue, Lexington, Massachusetts 02421
United States of America
Phone: +1.617.621.8097
Number of Employees: 302


Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.